These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 32788242

  • 1. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype.
    Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, Teunissen CE.
    Neurology; 2020 Oct 27; 95(17):e2378-e2388. PubMed ID: 32788242
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 27; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 3. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 4. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
    Sun X, Dong C, Levin B, Crocco E, Loewenstein D, Zetterberg H, Blennow K, Wright CB, Alzheimer's Disease Neuroimaging Initiative.
    Alzheimers Dement; 2016 Nov 29; 12(11):1159-1166. PubMed ID: 27321472
    [Abstract] [Full Text] [Related]

  • 5. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M.
    Alzheimers Res Ther; 2019 Dec 05; 11(1):99. PubMed ID: 31805990
    [Abstract] [Full Text] [Related]

  • 6. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB, Eldholm RS, Braekhus A, Engedal K, Saltvedt I.
    BMC Geriatr; 2017 Sep 11; 17(1):210. PubMed ID: 28893185
    [Abstract] [Full Text] [Related]

  • 7. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK, Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.
    Alzheimers Res Ther; 2017 Oct 23; 9(1):87. PubMed ID: 29061195
    [Abstract] [Full Text] [Related]

  • 8. Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.
    Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM.
    Neurobiol Aging; 2011 Aug 23; 32(8):1372-8. PubMed ID: 19748159
    [Abstract] [Full Text] [Related]

  • 9. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.
    Dement Geriatr Cogn Disord; 2009 Aug 23; 27(5):458-64. PubMed ID: 19420940
    [Abstract] [Full Text] [Related]

  • 10. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
    Wang S, Zhang J, Pan T, for Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2018 Oct 15; 685():109-113. PubMed ID: 30144541
    [Abstract] [Full Text] [Related]

  • 11. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, van der Flier WM, Scheltens P, van Berckel BNM, Bouwman F, Ossenkoppele R.
    Alzheimers Res Ther; 2019 Sep 12; 11(1):78. PubMed ID: 31511058
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ.
    BMC Neurol; 2015 Apr 01; 15():51. PubMed ID: 25880550
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.
    Ahmad S, Yang W, Orellana A, Frölich L, de Rojas I, Cano A, Boada M, Hernández I, Hausner L, Harms AC, Bakker MHM, Cabrera-Socorro A, Amin N, Ramírez A, Ruiz A, Van Duijn CM, Hankemeier T.
    Alzheimers Res Ther; 2024 Jul 30; 16(1):171. PubMed ID: 39080778
    [Abstract] [Full Text] [Related]

  • 17. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH, Cogo-Moreira H, Rabin JS, Black SE, Swardfager W, Alzheimer's Disease Neuroimaging Initiative.
    J Neurosci; 2019 Sep 11; 39(37):7428-7437. PubMed ID: 31350262
    [Abstract] [Full Text] [Related]

  • 18. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
    Skouras S, Torner J, Andersson P, Koush Y, Falcon C, Minguillon C, Fauria K, Alpiste F, Blenow K, Zetterberg H, Gispert JD, Molinuevo JL, ALFA Study.
    Brain; 2020 Mar 01; 143(3):976-992. PubMed ID: 32091109
    [Abstract] [Full Text] [Related]

  • 19. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
    Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR, Beckett LA, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ, Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Alzheimers Dement; 2015 Dec 01; 11(12):1417-1429. PubMed ID: 25960448
    [Abstract] [Full Text] [Related]

  • 20. Sex differences in the association between AD biomarkers and cognitive decline.
    Koran MEI, Wagener M, Hohman TJ, Alzheimer’s Neuroimaging Initiative.
    Brain Imaging Behav; 2017 Feb 01; 11(1):205-213. PubMed ID: 26843008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.